BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020;8:571. [PMID: 32733853 DOI: 10.3389/fchem.2020.00571] [Cited by in Crossref: 22] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Bajracharya R, Song JG, Patil BR, Lee SH, Noh HM, Kim DH, Kim GL, Seo SH, Park JW, Jeong SH, Lee CH, Han HK. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv 2022;29:1959-70. [PMID: 35762636 DOI: 10.1080/10717544.2022.2089296] [Reference Citation Analysis]
2 Kaur S, Pandey SK, Sharma D, Sharma RK, Wangoo N. Enkephalin loaded and RGD decorated PLGA–poloxamer nanoparticles for effective targeting in cancer cells. J Mater Sci. [DOI: 10.1007/s10853-022-07691-x] [Reference Citation Analysis]
3 Fatima M, Abourehab MAS, Aggarwal G, Jain GK, Sahebkar A, Kesharwani P. Advancement of cell-penetrating peptides in combating triple-negative breast cancer. Drug Discov Today 2022;27:103353. [PMID: 36099963 DOI: 10.1016/j.drudis.2022.103353] [Reference Citation Analysis]
4 Seo IH, Lee J, Na D, Kyung H, Yang J, Lee S, Jeon SJ, Choi JW, Lee KY, Yi J, Han J, Yoo M, Kim SH. The Anti-Tumor Effect of Boron Neutron Capture Therapy in Glioblastoma Subcutaneous Xenograft Model Using the Proton Linear Accelerator-Based BNCT System in Korea. Life (Basel) 2022;12:1264. [PMID: 36013445 DOI: 10.3390/life12081264] [Reference Citation Analysis]
5 Huang Q, Chen L, Liang J, Huang Q, Sun H. Neurotransmitters: Potential Targets in Glioblastoma. Cancers 2022;14:3970. [DOI: 10.3390/cancers14163970] [Reference Citation Analysis]
6 Furman O, Zaporozhets A, Tobi D, Bazylevich A, Firer MA, Patsenker L, Gellerman G, Lubin BCR. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery. Pharmaceutics 2022;14:1505. [DOI: 10.3390/pharmaceutics14071505] [Reference Citation Analysis]
7 Takada S, Kondo N, Hagimori M, Temma T. Development of a switching-type fluorescence sensor for the detection of boronic acid-containing agents. Anal Sci 2022. [PMID: 35796996 DOI: 10.1007/s44211-022-00158-8] [Reference Citation Analysis]
8 Chen X, Liu F, Yu X, Li L, Yan J, Chen X, Liu Q, Liu B. An auristatin-based peptide-drug conjugate targeting Kita-Kyushu lung cancer antigen 1 for precision chemoradiotherapy in gastric cancer. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114617] [Reference Citation Analysis]
9 Sigorski D, Różanowski P, Iżycka-Świeszewska E, Wiktorska K. Antibody-Drug Conjugates in Uro-Oncology. Target Oncol 2022. [PMID: 35567672 DOI: 10.1007/s11523-022-00872-3] [Reference Citation Analysis]
10 Tong S, Darwish S, Ariani HHN, Lozada KA, Salehi D, Cinelli MA, Silverman RB, Kaur K, Yang S. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022;14:1036. [DOI: 10.3390/pharmaceutics14051036] [Reference Citation Analysis]
11 Hwang JS, Kim SG, Shin TH, Jang YE, Kwon DH, Lee G. Development of Anticancer Peptides Using Artificial Intelligence and Combinational Therapy for Cancer Therapeutics. Pharmaceutics 2022;14:997. [DOI: 10.3390/pharmaceutics14050997] [Reference Citation Analysis]
12 Paulus J, Sewald N. Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin αVβ3. Front Chem 2022;10:869639. [DOI: 10.3389/fchem.2022.869639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Banerjee S, Chakraborty S, Majumder K. Rational design of bioactive chimeric construct by exploring archaeal antimicrobial peptides: an in silico approach. Biologia. [DOI: 10.1007/s11756-022-01071-1] [Reference Citation Analysis]
14 Mai R, Deng B, Zhao H, Li L, Fang Y, Li S, Deng X, Chen J. Design, Synthesis, and Bioevaluation of Novel Enzyme-Triggerable Cell Penetrating Peptide-Based Dendrimers for Targeted Delivery of Camptothecin and Cancer Therapy. J Med Chem 2022. [PMID: 35380045 DOI: 10.1021/acs.jmedchem.2c00287] [Reference Citation Analysis]
15 Chen W, Cai X, Sun Q, Guo X, Liang C, Tang H, Huang H, Luo H, Chen L, Chen J. Design and synthesis of aptamer-cyclometalated iridium(III) complex conjugate targeting cancer cells. Eur J Med Chem 2022;236:114335. [PMID: 35398732 DOI: 10.1016/j.ejmech.2022.114335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Dahri M, Abolmaali SS, Maleki R, Najafi H, Abedanzadeh M, Tamaddon AM. Nanoscale aggregation of doxorubicin-short peptide conjugates for enzyme-responsive delivery with various MOF carriers: In-silico steps towards smart cancer chemotherapy. Comput Biol Med 2022;144:105386. [PMID: 35272116 DOI: 10.1016/j.compbiomed.2022.105386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Xie D, Wang Z, Li J, Guo D, Lu A, Liang C. Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment. Front Oncol 2022;12:843345. [DOI: 10.3389/fonc.2022.843345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kim EH, Lee J, Kwak G, Jang H, Kim H, Cho H, Jang Y, Choi J, Chi S, Kim K, Kwon IC, Yang Y, Kim SH. PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.02.031] [Reference Citation Analysis]
19 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Wang L, Chen H, Wang F, Zhang X. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel. Expert Opin Drug Deliv 2022. [PMID: 35130795 DOI: 10.1080/17425247.2022.2039621] [Reference Citation Analysis]
21 Xu J, Li X, Du Y. Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer. Adv Biol (Weinh) 2022;:e2101065. [PMID: 35122418 DOI: 10.1002/adbi.202101065] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Hart LR, Lebedenko CG, Mitchell SM, Daso RE, Banerjee IA. In Silico Studies of Tumor Targeted Peptide-Conjugated Natural Products for Targeting Over-Expressed Receptors in Breast Cancer Cells Using Molecular Docking, Molecular Dynamics and MMGBSA Calculations. Applied Sciences 2022;12:515. [DOI: 10.3390/app12010515] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Jiang Y, Jiang Z, Wang M, Ma L. Current understandings and clinical translation of nanomedicines for breast cancer therapy. Adv Drug Deliv Rev 2022;180:114034. [PMID: 34736986 DOI: 10.1016/j.addr.2021.114034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Jendryczko K, Rzeszotko J, Krzyscik MA, Szymczyk J, Otlewski J, Szlachcic A. Peptibody Based on FGFR1-Binding Peptides From the FGF4 Sequence as a Cancer-Targeting Agent. Front Pharmacol 2021;12:748936. [PMID: 34867353 DOI: 10.3389/fphar.2021.748936] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Kaur J, Arroub K, Drzezga A, Schomäcker K, Mathur S. Synthesis, proteolytic stability, and in vitro evaluation of DOTA conjugated p160 peptide based radioconjugates: [177Lu]Lu-DOTA-p160. Org Biomol Chem 2021;19:9849-54. [PMID: 34755753 DOI: 10.1039/d1ob01812d] [Reference Citation Analysis]
26 Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, Malkas LH. Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells 2021;10:2908. [PMID: 34831131 DOI: 10.3390/cells10112908] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
27 Chugh V, Vijaya Krishna K, Pandit A. Cell Membrane-Coated Mimics: A Methodological Approach for Fabrication, Characterization for Therapeutic Applications, and Challenges for Clinical Translation. ACS Nano 2021. [PMID: 34699181 DOI: 10.1021/acsnano.1c03800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
28 Wang MD, Hou DY, Lv GT, Li RX, Hu XJ, Wang ZJ, Zhang NY, Yi L, Xu WH, Wang H. Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency. Biomaterials 2021;278:121139. [PMID: 34624753 DOI: 10.1016/j.biomaterials.2021.121139] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
29 Lindberg J, Nilvebrant J, Nygren PÅ, Lehmann F. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules 2021;26:6042. [PMID: 34641586 DOI: 10.3390/molecules26196042] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
30 Moody TW, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT. Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Front Endocrinol (Lausanne) 2021;12:728088. [PMID: 34539578 DOI: 10.3389/fendo.2021.728088] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Shoari A, Tooyserkani R, Tahmasebi M, Löwik DWPM. Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade. Pharmaceutics 2021;13:1391. [PMID: 34575464 DOI: 10.3390/pharmaceutics13091391] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
32 Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci 2021:S0165-6147(21)00136-X. [PMID: 34334251 DOI: 10.1016/j.tips.2021.07.001] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
33 Cooper BM, Iegre J, O' Donovan DH, Ölwegård Halvarsson M, Spring DR. Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs). Chem Soc Rev 2021;50:1480-94. [PMID: 33346298 DOI: 10.1039/d0cs00556h] [Cited by in Crossref: 10] [Cited by in F6Publishing: 52] [Article Influence: 10.0] [Reference Citation Analysis]
34 Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther 2021;21:945-62. [PMID: 34043927 DOI: 10.1080/14712598.2021.1936494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
35 Dymova MA, Kuligina EV, Richter VA. Molecular Mechanisms of Drug Resistance in Glioblastoma. Int J Mol Sci 2021;22:6385. [PMID: 34203727 DOI: 10.3390/ijms22126385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
36 Poplinger D, Bokan M, Hesin A, Thankarajan E, Tuchinsky H, Gellerman G, Patsenker L. Ratiometric Fluorescence Monitoring of Antibody-Guided Drug Delivery to Cancer Cells. Bioconjug Chem 2021. [PMID: 34115936 DOI: 10.1021/acs.bioconjchem.1c00205] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
37 Wanka L, Behr V, Beck-Sickinger AG. Arrestin-dependent internalization of rhodopsin-like G protein-coupled receptors. Biol Chem 2021. [PMID: 34036761 DOI: 10.1515/hsz-2021-0128] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
38 Song L, Ojeda‐carralero GM, Parmar D, González‐martínez DA, Van Meervelt L, Van der Eycken J, Goeman J, Rivera DG, Van der Eycken EV. Chemoselective Peptide Backbone Diversification and Bioorthogonal Ligation by Ruthenium‐Catalyzed C−H Activation/Annulation. Adv Synth Catal 2021;363:3297-304. [DOI: 10.1002/adsc.202100323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
39 Wolf P, Beck-Sickinger AG. The ring size of monocyclic ET-1 controls selectivity and signaling efficiency at both endothelin receptor subtypes. J Pept Sci 2021;27:e3325. [PMID: 33939217 DOI: 10.1002/psc.3325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Dahiya R, Dahiya S, Kumar P, Kumar RV, Dahiya S, Kumar S, Saharan R, Basu P, Mitra A, Sharma A, Kashaw SK, Patel JK. Structural and biological aspects of natural bridged macrobicyclic peptides from marine resources. Arch Pharm (Weinheim) 2021;354:e2100034. [PMID: 33913195 DOI: 10.1002/ardp.202100034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E. Theranostic Advances in Breast Cancer in Nuclear Medicine. Int J Mol Sci 2021;22:4597. [PMID: 33925632 DOI: 10.3390/ijms22094597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
42 Chu JCH, Fong WP, Wong CTT, Ng DKP. Facile Synthesis of Cyclic Peptide-Phthalocyanine Conjugates for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy. J Med Chem 2021;64:2064-76. [PMID: 33577327 DOI: 10.1021/acs.jmedchem.0c01677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ciaffaglione V, Waghorn PA, Exner RM, Cortezon-Tamarit F, Godfrey SP, Sarpaki S, Quilter H, Dondi R, Ge H, Kociok-Kohn G, Botchway SW, Eggleston IM, Dilworth JR, Pascu SI. Structural Investigations, Cellular Imaging, and Radiolabeling of Neutral, Polycationic, and Polyanionic Functional Metalloporphyrin Conjugates. Bioconjug Chem 2021;32:1374-92. [PMID: 33525868 DOI: 10.1021/acs.bioconjchem.0c00691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lee J, Kim C. Peptide Materials for Smart Therapeutic Applications. Macromol Res 2021;29:2-14. [DOI: 10.1007/s13233-021-9011-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zhou X, Smith QR, Liu X. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1695. [PMID: 33470550 DOI: 10.1002/wnan.1695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
46 Mironov AF, Ostroverkhov PV, Tikhonov SI, Pogorilyy VA, Kirin NS, Chudakova OO, Tsygankov AA, Grin MA. Amino acid derivatives of natural chlorins as a platform for the creation of targeted photosensitizers in oncology. Fine Chem Technol 2021;15:16-33. [DOI: 10.32362/2410-6593-2020-15-6-16-33] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
47 Wu Y, Williams J, Calder EDD, Walport LJ. Strategies to expand peptide functionality through hybridisation with a small molecule component. RSC Chem Biol 2021;2:151-65. [PMID: 34458778 DOI: 10.1039/d0cb00167h] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
48 Catalano M, Bassi G, Rotondi G, Khettabi L, Dichiara M, Murer P, Scheuermann J, Soler-Lopez M, Neri D. Discovery, affinity maturation and multimerization of small molecule ligands against human tyrosinase and tyrosinase-related protein 1. RSC Med Chem 2020;12:363-9. [PMID: 34041485 DOI: 10.1039/d0md00310g] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Akhter MH, Beg S, Tarique M, Malik A, Afaq S, Choudhry H, Hosawi S. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead. Biochim Biophys Acta Gen Subj 2021;1865:129777. [PMID: 33130062 DOI: 10.1016/j.bbagen.2020.129777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
50 Elleaume H, Barth RF, Rousseau J, Bobyk L, Balosso J, Yang W, Huo T, Nakkula R. Radiation therapy combined with intracerebral convection-enhanced delivery of cisplatin or carboplatin for treatment of the F98 rat glioma. J Neurooncol 2020;149:193-208. [PMID: 32809095 DOI: 10.1007/s11060-020-03600-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]